Skip to main content

Market Overview

AbbVie: Q1 Earnings Insights



Shares of AbbVie (NYSE:ABBV) rose 1.5% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 21.90% over the past year to $2.95, which beat the estimate of $2.83.

Revenue of $13,010,000,000 rose by 50.95% year over year, which beat the estimate of $12,760,000,000.


The upcoming fiscal year's EPS expected to be between $12.37 and $12.57.

Details Of The Call

Date: Apr 30, 2021

Time: 09:00 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $113.41

Company's 52-week low was at $79.11

Price action over last quarter: Up 3.65%

Company Overview

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.


Related Articles (ABBV)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at